Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection.
Elham Beyranvand NejadRobert B RattsEleni PanagiotiChristine MeyerJennifer D OduroLuka Cicin-SainKlaus FrühSjoerd H van der BurgRamon ArensPublished in: Journal for immunotherapy of cancer (2019)
This study highlight the effectiveness of CMV-based vaccine vectors, and shows that demarcated thresholds of vaccine-specific T cells could be defined that correlate to tumor protection. Together, these results may hold importance for cancer vaccine development to achieve high efficacy in vaccine recipients.